Abstract
Purpose: This study is to document the activity and acceptability for a new topical agent, A-007, in the treatment of cutaneous metastases from cancer. Patients and methods: This is a multicenter study involving 27 patients with inoperable skin lesions from histologically confirmed cancers of the breast and oral cavity, non-Hodgkin’s lymphoma, Kaposi’s sarcoma, and angiosarcoma that had failed radiotherapy or systemic treatment. A-007, as a 0.25% gel, was applied twice daily to the areas of cancer to be measured as well as applied to a healthy control area distant from the cancer areas. An untreated cancer area was also included and documented as a cancer control. Results: The overall objected response rate with A-007 was 26%, with an additional 19% minimum response/stabilization of cancer. For patients with breast cancer, hormonal status did not have an impact on response. The median duration of response was 15 weeks (with one patient having a response for 3.5 years). Toxicities observed were itching, burning, and a rash, in 6 of the 27 patients. The skin toxicities were in the cancer-treated fields; none were observed in the A-007 control areas. All irritated areas cleared while continuing treatment, and the tumor lesions in the areas of itching also improved. Conclusion: A-007, as a 0.25% gel, is confirmed as an effective palliative treatment option for cutaneous metastases from cancers. Skin reactions were minimal, tolerated, and no cessation of treatment was required.
Abbreviations
- A-007:
-
4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
References
Cantu’ de Leon D, Alanis-Lopez P, Rodriguez-Trejo A et al (2003) Chestwall resection in breast cancer recurrence. In: 14th international congress on anti-cancer treat, Paris, pp 156–157
Leonard R, Hardy J, Van Tienhoven G, et al (2001) Randomized double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. J Clin Oncol 19:4150–4159
Maxfield WS (1967) Panel discussion—theory of recurrent disease. In: Segaloff A, Meyer KK, Debakay S (eds) Current concepts breast cancer, The Williams and Wilkins Co, Baltimore, pp 364–367
Barnhill RL, Mihm MC Jr (1992) Histopathology of malignant melanoma and its precursor lesions. In: Blach CM, Houghton AN, Milton GW, Sober AJ (eds) Cutaneous melanoma. JB Lippincott Co. Phil, PA, pp 234–263
Sezary A, Bouvrain Y (1938): Erythrodermine avec presence de cellules monstrueses dans le derme et dans le sang circulant. Bull Soc Fr Dermatol Symp 45:254–265
Safi B (1987) Pathophysiology and epidemiology of epidemic Kaposi’s sarcoma. Semin Oncol 14 (suppl):7–23
Morgan LR, Judge KW, Gillen LE, Fan D, Leclercq G (1988) Substituted benzo-phenone phenylhydrazones for the treatment of hormone dependent tumors. Proc Am Assoc Cancer Res 25:243
Morgan LR, Rodgers AH, Hooper CL et al (2001) Comparative dermal pharmacology and toxicology of 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rodents and primates. In Vivo 15:479–484
Morgan LR, Jursic B, Morgan LR, et al (2002) Anticancer activity for 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone analogs and their ability to interact with lymphoendothelial cell surface markers. Bioorg Med Chem Lett 12:3407–3411
Morgan LR, Rodgers A, Fan D, et al (1997) Comparative preclinical toxicology and pharmacology of 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vivo in rodents and primates. In Vivo 11:29–38
Morgan LR, Thangaraj K, LeBlanc B, et al (2003) Design, synthesis, and anticancer properties of 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogs. J Med Chem 46:4552–4563
Eilender DE, LoRusso P, Krementz ET et al (1998) Topical use of 4,4′-dihydroxy-benzophenone-2,4-dinitrophenylhydrazone (A-007) as a 0.25% gel in the treatment of malignant cutaneous metastases—a phase I study. In: Proceedings of the 10th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, NL 477 (abstr)
Eilender DE, McCormick C, Tornyos K (1999) Recurrent CD30/K1-1—positive lymphoma of the skin treated with topical 4,4′-dihydroxybenzo-phenone-2,4-dinitrophenylhydrazone (A-007) as a 0.25% gel. Proc Amer Soc Clin Onc 18:96 (abstr)
Rodgers AH, Subramanian S, Morgan LR (1995) High performance liquid chromatographic determination of 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in plasma. J Chrom 670:365–368
Corbett TH, Lowichik N, Pugh S, Polin L, Panchapor C, White K, Knight J, Demchik L, Jones J, Jones L, Biernat L, LoRusso P, Foster B, Heibrun L, Rake J, Mattes KC, Perni R, Powles RG, Hiavac AG, Wentland MP, Coughlin SA, Baker L, Valeriote, F (1994) Antitumor activity of N-1-[[2-(dialkyamino) ethyl] amino]-9-oxo-9H-thioxanthen-4-yl-(methyl) methane sulfonamide (WYN 333777) and analogs. Exp Opin Investig Drugs 3(12):1281–1292
Thangaraj K, Morgan LR Benes E et al (1993) Aryl-2,4-dinitrophenylhudrazone anticancer activities in vitro against fresh human cancer cells. Breast Cancer Res Treat 21:21 (abstr)
Morgan LR, Rodgers AH, LeBlanc BW, Boue SM, Yang Y, Jursic BS, Cole RB (2001) Anticancer properties for 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-00)/3,7-diaminophenothiazine-5-ium double salts.Bioorg Med Chem Lett 11:2193–2195
Easmon J, Heinisch G, Purstinger G et al (2000) Synthesis and cytotoxic evaluation of analogs of the antiestrogenic agent 4,4′-dihydroxybenzophenone-2,4-dinitrophenylhydrazone. Proc Am Assoc Cancer Res 41:656 (abstr)
Acknowledgements
This work was supported by grants CA 49310, CA 16672, and CA 89772 from the NCI/SBIR and FLAIR programs.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented in part as an abstract poster: 10th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, 1998.
Rights and permissions
About this article
Cite this article
Eilender, D., LoRusso, P., Thomas, L. et al. 4,4′-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): a topical treatment for cutaneous metastases from malignant cancers. Cancer Chemother Pharmacol 57, 719–726 (2006). https://doi.org/10.1007/s00280-005-0124-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0124-2